Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIO-Europe: Rimonabant in Obesity
NCT00386061Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2001
- Primary completion
- Jun 2004
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of rimonabant in obesity (3 arms), sponsored by Sanofi. Primary endpoint: Change in body weight at 1 year. Started Oct 2001; status: completed.
02
Drugs
rimonabant
03
Conditions
obesity
Beyond the preview
Go deeper on NCT00386061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00386061.